Nano-Laser Technology Could Eliminate Coronavirus from Bodies of COVID-19 Patients
By HospiMedica International staff writers Posted on 22 Jul 2020 |
Illustration
A patent pending treatment aims to use laser technology to eradicate the COVID-19 coronavirus by introducing one or more fluorescent antibody-antigen complexing agents to bind with the target antigen(s) (i.e., COVID-19 target antigens).
The technology has been developed by Halberd Corp. (Jackson Center, PA, USA) and will allow the virus to be seen and located, and allow for eradicating the fluorescent antibody-antigen complex by utilizing an energy burst from a nano-laser, with the removal of the debris through conventional mechanical filtering. The method entails the extracorporeal (outside the body) treatment of a patient's blood (for blood-borne diseases) or cerebrospinal fluid (CSF - for neurological diseases) consisting of a four-step process, including removal of bodily fluid from the patient; introduction of antibody-antigen complexing agent(s) to bind with the target antigen(s) (i.e., COVID-19 target antigens), eradicate the fluoresced antibody-antigen complex with a nano-laser and removal of the debris; and return of the cleansed bodily fluid to the patient.
This process is intended to be performed during a continuous-flow operation, similar to normal dialysis. By treating the blood or CSF outside of the patient, and using complexing agents which combine only with antigens associated with COVID-19, negative side-effects and reactions can be greatly reduced or eliminated.
“This process is intended to eliminate COVID-19 coronavirus, and its mutations from a patient's body. The use of a nano-laser and the associated complex computer controlled targeting system, should allow for a great flexibility in selecting and eliminating disease antigens, said Dr. Mitchell S. Felder, who invented the treatment.
“COVID-19 is a complex and virulent virus. We decided to pursue several alternatives of varying complexities in an attempt to address the complete elimination of the virus, and to develop an effective treatment protocol,” said William A. Hartman, Chairman, President & CEO of Halberd Corporation.
Related Links:
Halberd Corp.
The technology has been developed by Halberd Corp. (Jackson Center, PA, USA) and will allow the virus to be seen and located, and allow for eradicating the fluorescent antibody-antigen complex by utilizing an energy burst from a nano-laser, with the removal of the debris through conventional mechanical filtering. The method entails the extracorporeal (outside the body) treatment of a patient's blood (for blood-borne diseases) or cerebrospinal fluid (CSF - for neurological diseases) consisting of a four-step process, including removal of bodily fluid from the patient; introduction of antibody-antigen complexing agent(s) to bind with the target antigen(s) (i.e., COVID-19 target antigens), eradicate the fluoresced antibody-antigen complex with a nano-laser and removal of the debris; and return of the cleansed bodily fluid to the patient.
This process is intended to be performed during a continuous-flow operation, similar to normal dialysis. By treating the blood or CSF outside of the patient, and using complexing agents which combine only with antigens associated with COVID-19, negative side-effects and reactions can be greatly reduced or eliminated.
“This process is intended to eliminate COVID-19 coronavirus, and its mutations from a patient's body. The use of a nano-laser and the associated complex computer controlled targeting system, should allow for a great flexibility in selecting and eliminating disease antigens, said Dr. Mitchell S. Felder, who invented the treatment.
“COVID-19 is a complex and virulent virus. We decided to pursue several alternatives of varying complexities in an attempt to address the complete elimination of the virus, and to develop an effective treatment protocol,” said William A. Hartman, Chairman, President & CEO of Halberd Corporation.
Related Links:
Halberd Corp.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans